14055-37-9

Upstream product

• 2890-98-4 exo-5-norbornen-2-ol 
• 694-97-3 endo-5-norbornen-2-ol 
• 25125-21-7 4-(hydroxymethyl)cyclopentene 
• 71338-98-2 p-Toluolsulfonsaeure-<6endo-brom-2endo-norbornyl>ester 

Downstream Products

• 197227-61-5 (S)-4-benzyl-3-[(2S,3R)-4-cyclopent-3-enyl-3-hydroxy-2-methylbutanoyl]-oxazolidin-2-one 
• 910223-57-3 2-oxo-1,2,3,3a,4,6a-hexahydro-pentalene-1-carboxylic acid 2-oxo-1-phenyl-2-pyrrolidin-1-yl-ethyl ester 
• 910223-55-1 4-cyclopent-3-enyl-2-diazo-3-oxo-butyric acid 2-oxo-1-phenyl-2-pyrrolidin-1-yl-ethyl ester 
• 423116-50-1 9-(tert-butyl-dimethyl-silanyloxy)-7-[5-(tert-butyl-diphenyl-silanyloxy)-2-methoxy-1,3-dimethyl-pent-3-enyl]-10,14-dimethyl-6,16-dioxa-bicyclo[13.3.1]nonadeca-3,10,12-triene-5,17-dione 
• 197227-83-1 (S)-4-Benzyl-3-[(2S,3R)-4-cyclopent-3-enyl-2-methyl-3-(tetrahydro-pyran-2-yloxy)-butyryl]-oxazolidin-2-one 

Relevant academic research and scientific papers

Preparation method and intermediate of fused tricyclic derivative

The invention provides a preparation method of a fused tricyclic derivative intermediate. The intermediate has a structure shown as a formula (4-7). The preparation method has the advantages of accessible raw materials and simple steps and is suitable for large-scale industrial production.

A novel synthesis of bicyclo[3.3.0]octane ring system via a desymmetric C-H insertion reaction

An optically active bicyclo[3.3.0]octane ring was synthesized by an intramolecular C-H insertion reaction. Upon treatment with a catalytic amount of Rh2(S-DOSP)4, a chiral-auxiliary-containing diazoester underwent a C-H insertion reaction to give the desired bicyclo[3.3.0]octane system. Georg Thieme Verlag Stuttgart.

4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL- 2-ONES AS AGONISTS OF THE ALPHA- 2B AND ALPHA-2C ADRENERGIC RECEPTORS

Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.

Polar versus Steric Effects in the Solvolysis of 6endo-substituted 2endo-Norbornyl p-Toluenesulfonates

The solvolysis rates and products of the 6endo-R-substituted 2endo-norbornyl toluenesulfonates 6a-6i have been determined.The rates of 6a-6g correlate with the inductive constants ?qI of the 6endo-substituents and are not related to the size of the latter.It is therefore concluded that polar rather than steric effects control the exo/endo-rate ratios of norbornyl sulfonates.Products are derived mainly from rearranged 6exo-R-norbornyl cations when the substituent is an electron donor and from unrearranged 6endo-R-substituted cations when the substituent is an electron acceptor.

Synthese und Hydrolyse von 6endo-substituierten p-Toluolsulfonsaeure-estern.

The Synthesis and Hydrolysis of 6endo-Substituted 2endo-Norbornyl p-Toluenesulfonates; The hydrolysis products of the p-toluenesulfonates of several hitherto unknown 6endo-substituted 2endo-norbornanols have been determined.